Skip to main content
Tech.euFundingExplorerBeta

AnaCardio

AnaCardio is a privately held clinical stage biopharmaceutical company developing novel drugs to treat heart failure.

Total raised
€14M
€14,069,647
Funding rounds
1
Investors
5
distinct backers
Active since
2022-09
latest 2022-09

Funding by year

EUR raised per year

Signals

High confidence
Raise-next likelihood32
base rate 44% for Series A
  • Overdue vs cohort gap
  • Low backer re-investment

Timing: overdue vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.

Related news

Similar companies

same sector or country